Avadel Pharmaceuticals Ownership

AVDL Stock  USD 7.91  0.23  2.99%   
Avadel Pharmaceuticals holds a total of 96.27 Million outstanding shares. The majority of Avadel Pharmaceuticals PLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Avadel Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Avadel Pharmaceuticals. Please pay attention to any change in the institutional holdings of Avadel Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
1996-03-31
Previous Quarter
96.2 M
Current Value
96.3 M
Avarage Shares Outstanding
31.9 M
Quarterly Volatility
20.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Avadel Stock Ownership Analysis

About 80.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Avadel Pharmaceuticals recorded a loss per share of 1.09. The entity had not issued any dividends in recent years. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Avadel Pharmaceuticals is traded on NASDAQ Exchange in the United States. For more info on Avadel Pharmaceuticals PLC please contact the company at 353 1 901 5201 or go to https://www.avadel.com.
Besides selling stocks to institutional investors, Avadel Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Avadel Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Avadel Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Avadel Pharmaceuticals Quarterly Liabilities And Stockholders Equity

158.25 Million

Avadel Pharmaceuticals Insider Trades History

About 5.0% of Avadel Pharmaceuticals PLC are currently held by insiders. Unlike Avadel Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Avadel Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Avadel Pharmaceuticals' insider trades
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Avadel Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Avadel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avadel Pharmaceuticals PLC backward and forwards among themselves. Avadel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Avadel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goldman Sachs Group Inc2024-12-31
2.1 M
Tri Locum Partners Lp2024-12-31
1.9 M
State Street Corp2024-12-31
1.7 M
Ubs Group Ag2024-12-31
1.6 M
Tang Capital Management Llc2024-12-31
1.5 M
Millennium Management Llc2024-12-31
1.2 M
Morgan Stanley - Brokerage Accounts2024-12-31
1.2 M
Geode Capital Management, Llc2024-12-31
1.2 M
Checkpoint Capital Lp2024-12-31
M
Hhg Plc2024-12-31
14.1 M
Gendell Jeffrey L2024-12-31
6.3 M
Note, although Avadel Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Avadel Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avadel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avadel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avadel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Palczuk Linda over a month ago
Disposition of 25000 shares by Palczuk Linda of Avadel Pharmaceuticals at 10.93 subject to Rule 16b-3
 
Palczuk Linda over a month ago
Acquisition by Palczuk Linda of 5000 shares of Avadel Pharmaceuticals at 7.928 subject to Rule 16b-3
 
Palczuk Linda over two months ago
Disposition of 3500 shares by Palczuk Linda of Avadel Pharmaceuticals subject to Rule 16b-3
 
Gregory Divis over two months ago
Acquisition by Gregory Divis of 402 shares of Avadel Pharmaceuticals at 9.82 subject to Rule 16b-3
 
Palczuk Linda over two months ago
Acquisition by Palczuk Linda of 3000 shares of Avadel Pharmaceuticals at 10.1892 subject to Rule 16b-3
 
Palczuk Linda over three months ago
Disposition of 11000 shares by Palczuk Linda of Avadel Pharmaceuticals at 16.32 subject to Rule 16b-3
 
Glass Geoffrey Michael over three months ago
Disposition of 11000 shares by Glass Geoffrey Michael of Avadel Pharmaceuticals at 16.32 subject to Rule 16b-3
 
Thomas McHugh over six months ago
Acquisition by Thomas McHugh of 2000 shares of Avadel Pharmaceuticals at 14.5 subject to Rule 16b-3
 
Mccamish Mark Anthony over six months ago
Disposition of 75000 shares by Mccamish Mark Anthony of Avadel Pharmaceuticals at 14.53 subject to Rule 16b-3
 
Glass Geoffrey Michael over six months ago
Acquisition by Glass Geoffrey Michael of 11000 shares of Avadel Pharmaceuticals at 16.32 subject to Rule 16b-3
 
Amin Naseem over six months ago
Insider Trading
 
Jerad Seurer over six months ago
Disposition of 125000 shares by Jerad Seurer of Avadel Pharmaceuticals at 13.57 subject to Rule 16b-3

Avadel Pharmaceuticals Outstanding Bonds

Avadel Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avadel Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avadel bonds can be classified according to their maturity, which is the date when Avadel Pharmaceuticals PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Avadel Pharmaceuticals Corporate Filings

14th of February 2025
Other Reports
ViewVerify
F4
28th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
8th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
1.036
Quarterly Revenue Growth
26.743
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.